Key result
Cystamine dose-dependently improved the 35-day survival rate of rats with monocrotaline-induced pulmonary arterial hypertension, reaching 91.7% at /kg/day compared to 33.3% with monocrotaline alone.
Why the study?
Does cystamine improve survival and prevent the progression of monocrotaline-induced pulmonary arterial hypertension in rats?
Does cystamine improve survival and prevent the progression of monocrotaline-induced pulmonary arterial hypertension in rats?
Cystamine improves survival and delays, but does not reverse, the progression of monocrotaline-induced pulmonary arterial hypertension in rats by inhibiting TG2 and downstream Akt/ERK pathways.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of cystamine in PAH; hypothesis-generating for TG2 inhibition in human trials.
Tissue transglutaminase (TG2) plays an important role in pulmonary arterial hypertension (PAH). Previous research indicate that TG2 and protein serotonylation catalyzed by TG2 are upregulated in PAH. Serotonin transporter inhibitor fluoxetine ameliorates PAH via inhibition of protein serotonylation. It is still unknown whether PAH is inhibited through direct inhibition of TG2. Therefore, the present study aimed to investigate the effects of TG2 inhibitor cystamine on monocrotaline-induced PAH in rats. Rats were treated with monocrotaline (60 mg·kg −1 , i.p.) in combination with or without cystamine (20, 40 mg·kg −1 ·day −1 , p.o.). The results showed that compared with monocrotaline alone, combination of monocrotaline with cystamine (40 mg·kg −1 ·day −1 , p.o.) relieved right ventricle hypertrophy, inhibited pulmonary arteriolar remodeling, and downregulated protein expression of TG2, phosphorylated protein kinase B (Akt), and extracellular regulated protein kinase (ERK) at day 21. However, except for TG2 expression, these changes were not significantly inhibited by cystamine at day 35. In addition, cystamine dose-dependently enhanced the survival rate of rats injected with monocrotaline at day 35. The findings suggest that cystamine slows but not reverses monocrotaline-induced PAH in rats, which was largely associated with the inhibition of TG2 protein expression and Akt and ERK activation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) studied Pulmonary arterial hypertension (n=98). Cystamine vs. Monocrotaline alone (vehicle) was evaluated on Survival rate at day 35. Cystamine dose-dependently improved the 35-day survival rate of rats with monocrotaline-induced pulmonary arterial hypertension, reaching 91.7% at /kg/day compared to 33.3% with monocrotaline alone.
Synapse has enriched 10 related papers. Consider them for comparative context: